Colorectal Cancer Metastatic Clinical Trial
— REGAINOfficial title:
A Phase II Study of Cetuximab Rechallenge in Combination With Irinotecan in Advanced Metastatic Colorectal Cancer Without KRAS or NRAS or BRAF Mutation (All Wild Type) for Patients Pretreated With FOLFIRI and Cetuximab in First Line With Stopping Cetuximab for Progressive Disease After a Previous Response (Partial Response or Complete Response) and After Treatment With a Fluoropyrimidine, Oxaliplatin Plus Bevacizumab Regimen
Verified date | January 2017 |
Source | Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main objective of this study is to evaluate the objective response rate at two months
(complete disappearance of the disease and partial disappearance of the disease) obtained
after administration of combination therapy with cetuximab and irinotecan in the patients
with metastatic colorectal cancer.
Secondaries objectives will be assessed progression-free survival, overall survival,
toxicity, quality of life.
Status | Terminated |
Enrollment | 2 |
Est. completion date | January 2017 |
Est. primary completion date | January 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Signed and dated informed consent - Histologically confirmed metastatic adenocarcinoma of the colon or rectum - All Wild Type KRAS (exon 2 [codons 12-13], exon 3 [codons - 61]; exon 4 [codon 146]), NRAS (exon 2 [ codons 12-13] and exon 3 [codon 61) and BRAF (V600E) tumor ( local assessment performed either on primary tumor or metastasis) - First line chemotherapy regimen with a fluoropyrimidine and Irinotecan (FOLFIRI) + cetuximab with initial partial or complete response and progressive disease (PD) with PD = 6 weeks after the last administration of cetuximab - Other line(s) of therapy(ies) including the following drugs: second line oxaliplatin based chemotherapy with fluoropyrimidines (5FU or capecitabine) + bevacizumab and eventually regorafenib (possible but not mandatory) and progression or limiting toxicity to the last therapy with a minimum of 4 months between last injection of cetuximab and inclusion in this study - At least one measurable lesion = 10 mm as assessed by CT-scan or MRI (Magnetic Resonance Imaging) according to RECIST v1.1 (All sites must be evaluated = 28 days prior to the enrolment) - Age =18 years - World Health Organization (WHO) Performance status (PS) 0-2 - The patient has adequate organ function, defined as : Absolute neutrophil count (ANC) = 1.5 x 109/L, hemoglobin = 9 g/dL, and platelets = 100 x 109/L.Total bilirubin = 1.5 times upper limit of normal value (ULN), serum alkaline phosphatase level < 5 times ULN, Serum creatinine level <150µM/l - For female patients of childbearing potential, negative pregnancy test within 7 days before starting the study drug - Men and women are required to use adequate birth control during the study (when applicable) and until 6 months after the end of study treatment - Registration in a national health care system (CMU included) Exclusion Criteria: - Previous chemotherapy other than adjuvant therapy with different combinations than those scheduled in first and second line treatment - Presence of any KRAS, BRAF or NRAS mutation by allelic discrimination on tumor DNA - Significant cardiovascular disease including unstable angina or myocardial infarction within 12 months before initiation of study treatment or a history of ventricular arrhythmia (treated or not) - History or evidence of central nervous system metastasis (systematic CT-scan or MRI not mandatory if no clinical symptoms) - Known allergy or hypersensitivity to cetuximab - Previous or concurrent malignancy except for basal or squamous cell skin cancer, in situ carcinoma of the cervix, low-risk prostate cancer according to d'Amico classification or other solid tumors treated curatively and without evidence of recurrence for at least 5 years prior to the study - Active or uncontrolled clinically serious infection - Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness - Other serious and uncontrolled non-malignant disease - Pregnancy - Breast feeding - Treatment with any other investigational medicinal product within 28 days prior to study entry - Known Gilbert's syndrome - Concomitant administration of live, attenuated virus vaccine such as yellow fever vaccine - Concomitant use with St John's Wort - Chronic inflammatory bowel disease and/or Bowel obstruction |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Beaujon | Clichy | |
France | Centre hospitalier Alpes Leman | Contamine sur Arve | |
France | Centre Georges François Leclerc | Dijon | |
France | CHD Vendée | La Roche/ Yon | |
France | Hôpital Privé Jean Mermoz | Lyon | |
France | Hôpital Européeen | Marseille | |
France | Institut Paoli-Calmettes | Marseille | |
France | CHU Caremeau | Nîmes | |
France | CHU Cochin | Paris | |
France | Hôpital Pitié Salpêtrière | Paris | |
France | Hôpital Saint Antoine | Paris | |
France | Hôpital Saint Louis | Paris | |
France | Hôpital Tenon | Paris | |
France | Clinique Armoricaine de Radiologie | Saint Brieuc | |
France | Groupe hospitalier Public du Sud de l'Oise -site de Senlis | Senlis | |
France | Centre de radiothérapie - Clinique Sainte Anne | Strasbourg | |
France | Hôpital Foch | Suresnes | |
France | Hôpitaux du Léman | Thonon les Bains | |
France | CHU Tours - Hôpital Trousseau | Tours | |
France | Clinique Générale | Valence |
Lead Sponsor | Collaborator |
---|---|
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response rate (ORR) | At 2 months | ||
Secondary | Objective response rate (ORR) | Best response observed during investigational treatment combination. From the start of treatment until treatment failure | up to 27 months | |
Secondary | Disease control rate (DCR) | The proportion of patients with tumor response (Complete response or partial response) or tumor stabilization as best response during study treamtent | up to 27 months | |
Secondary | Progression-free survival (PFS) | Time from the date of inclusion to the date of the first progressive disease (RECIST criteria) or death (any cause) | up to 27 months | |
Secondary | Duration of response (DOR) | Only for patients with tumor response (complete reposne or partial response) , from first confirmed response to first observed progression (PD) or death due to PD during study treatment | up to 27 months | |
Secondary | Time to response (TTR) | Time from the date of inclusion to the date of the first confirmed CR or PR during study treatment | up to 27 months | |
Secondary | Time to progression (TTP) | Time from the date of inclusion to the date of the first obseved progression (PD), or death due to progression during the study treatment | up to 27 months | |
Secondary | Time to treatment failure (TTF) | Time from the date of inclusion to the date the decision was made to end the study treatment for any reason | up to 27 months | |
Secondary | Duration of stable disease (DoSD) | Only for patient with a stable disease (SD) as best response during the study treatment, from date of inclusion to the first observed progression (PD) or death due to progression | up to 27 months | |
Secondary | Overall survival (OS) | From the date of inclusion to the date of patient death, due to any cause, or to the last date the patient was known to be alive | up to 27 months | |
Secondary | Adverse Events (CTCAE v.4.03) | Up to 27 months | ||
Secondary | Quality of life | Using EORTC Quality of Life Questionnaire - C30 (QLQ-C30) and the Dermatology Life Quality Index (DLQI ) questionnaires | Up to 27 months | |
Secondary | Respose rate | RAS and BRAF status in circulating tumoral DNA | up to 27 months | |
Secondary | PFS | RAS and BRAF status in circulating tumoral DNA | up to 27 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03941080 -
Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
|
||
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Completed |
NCT03647839 -
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT05057052 -
Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis
|
Phase 2 | |
Completed |
NCT03251612 -
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02380443 -
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT02149784 -
Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients
|
Phase 3 | |
Recruiting |
NCT01959061 -
Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
|
Phase 4 | |
Terminated |
NCT01668680 -
Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma
|
Phase 2 | |
Recruiting |
NCT05068531 -
Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
|
||
Not yet recruiting |
NCT04525807 -
Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
|
||
Completed |
NCT04482608 -
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
|
||
Recruiting |
NCT03193710 -
The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved
|
N/A | |
Recruiting |
NCT04854213 -
PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)
|
N/A | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03142516 -
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
|
Phase 2 | |
Completed |
NCT03144804 -
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01910610 -
Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer
|
Phase 3 | |
Recruiting |
NCT05759728 -
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04874207 -
Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib
|
Phase 4 |